Data / Form D filings / Gemin X Pharmaceuticals Inc
Gemin X Pharmaceuticals Inc: Form D filings
Gemin X Pharmaceuticals Inc, a biotechnology company in Malvern, PA, filed 2 Form D notices with the SEC between 2009 and 2010. The latest, on May 14, 2010, reports $3.9 million sold of a $8.5 million offering to 16 investors.
Find out what Gemin X Pharmaceuticals Inc does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 400 Chesterfield Parkway, Suite 100, Malvern, PA, 19355
- Phone
- (514) 281-8989
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2007
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1407168
The full lists. Form D filings in Pennsylvania: 987 rows, $49.35, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 14, 2010 | New notice | $8,500,000 | $3,916,229 | $4,583,771 | 16 | May 7, 2010 | sec.gov |
| Jun 12, 2009 | New notice | $20,000,000 | $9,259,078 | $10,740,922 | 24 | May 29, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Gordon C. Shore | Executive Officer, Director | |
| Robert J. Gorman | Director | |
| Timothy J. Barberich | Director | |
| Andrew R. Jordan | Director | |
| Robert G. McNeil | Director | |
| Scott J. Morenstein | Director | |
| Jean Michael Viallet | Executive Officer | |
| D. Michael Dixon | Executive Officer | |
| Eric W. Roberts | Director | |
| Peter R. Dolan | Executive Officer, Director |
Other biotechnology companies in Pennsylvania that filed recently
- Traws Pharma, Inc. offering · Nov 5, 2026
- BioLattice Ophthalmics, Inc, $1.8 million · Oct 28, 2026
- Myris Therapeutics, Inc. $500,000 · Oct 14, 2026
- Praeventix, Inc. $5.6 million · Sep 10, 2026
- Plowshare Therapies LLC $6.7 million · Aug 31, 2026
- Noveome Biotherapeutics, Inc. $6.8 million · Aug 27, 2026
- AlloTRx Bio Inc. $500,000 · Aug 24, 2026
- Aposture Surgical Corp $87,000 · Aug 13, 2026
- Merlin Biotech, Inc. $50,000 · Aug 11, 2026
Every Form D from the week of May 10, 2010 · All recent filings in Pennsylvania · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Gemin X Pharmaceuticals Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.